Alpha-1 Antitrypsin Deficiency (AATD)
What is Alpha-1 Antitrypsin Deficiency?
AATD is an inherited, genetic, autosomal co-dominant disorder caused by mutations in the SERPINA1 gene, with the most frequent deficient variants coming from the Z (Glu342Lys) and S alleles (Glu264Val). The presence of Z alleles results in misfolding and polymerization of the AAT, leading to over 95% of severe AATD patients being PIZZ.
About YOLT-202
YOLT-202 is an in vivo gene-editing therapy that corrects PiZ mutation to PiM for the treatment of AATD. Utilizing YolTech’s proprietary adenine base editor, YOLT-202 is engineered to achieve on-target editing with minimal bystander activity.
Latest News
-
Oct 23, 2026
YolTech Announces Interim Clinical Data from Investigator-Initiated Trials of YOLT-203 in Primary Hyperoxaluria Type 1 to be Presented at the American Society of Nephrology (ASN) Kidney Week 2026Read More
-
Oct 14, 2026
YolTech Appoints Nitin Patel, BM BCh, as U.S. Chief Medical OfficerRead More
-
Sep 07, 2026
YolTech Presented Proof-of-Concept Data from Clinical Trial of YOLT-202 in PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Patients at European Respiratory Society Congress 2026Read More
